3 ms·

The drug in question is a Monoclonal Antibody (mab) intended to boost immune response. [1] Mabs do have a tendency to runaway reactions. [2]. Mab treatments ar

by csours 11y ago

The drug in question is a Monoclonal Antibody (mab) intended to boost immune response. [1] Mabs do have a tendency to runaway reactions. [2]. Mab treatments are likely to explode in coming years as immunomodulators to both boost the immune system to fight disease and suppress immune reactions in autoimmune diseases (some arthritis, asthma, severe allergies, etc) You have to dig to find this information, posting it here for visibility. 1. https://en.wikipedia.org/wiki/TGN1412 https://en.wikipedia.org/wiki/TGN1412 2. http://www.ncbi.nlm.nih.gov/pubmed/20305665 http://www.ncbi.nlm.nih.gov/pubmed/20305665

deleted 11y ago
[deleted]
awalton 11y ago
I found a French website claiming the drug is BIA 10-2474, with reference to a patient who received an offer to join this trial but decided not to: http://www.breizh-info.com/2016/01/15/rennes-biotrial-bialessai-therapeutique/ http://www.breizh-info.com/2016/01/15/rennes-biotrial-biales... And of course, the information around this particular drug is completely missing or intentionally vague. edit: there seems to be a lot of people who believe the drug is a FAAH2 inhibitor, based on previous work from the same company, Bial Pharmaceuticals out of Portugal. The drug works on/around endocannabinoids, which might be why the media was confused about this being cannibis related.
- gerbilly 11y ago
  In the video they say that the drug in question is intended to control pain via the endocannabinoid system. She was also very careful to insist that the drug neither contains cannabis or any substance derived from cannabis.
gregmac 11y ago
TGN1412 was a different trial that happened in 2006: it's mentioned in the article as a similar incident because it hospitalized six men.
- csours 11y ago
  Sorry about that, article was confusing.
jonlucc 11y ago
I believe the drug you reference is discussed as a previous case in which people were injured during clinical trials. The current casualties are part of a test of a different investigational cannabinoid pain-killer.
csours 11y ago
Replying as I can no longer update: I misread the article. I would follow this post [1] by Derek Lowe for more accurate info. If preliminary reports are correct the drug in question may be a FAAH inhibitor [2] which could lead to increased Andandamide [3] 1. http://blogs.sciencemag.org/pipeline/archives/2016/01/15/a-clinical-disaster-in-france http://blogs.sciencemag.org/pipeline/archives/2016/01/15/a-c... 2. https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase 3. https://en.wikipedia.org/wiki/Anandamide https://en.wikipedia.org/wiki/Anandamide
drmilsurp 11y ago
I see in later replies that this was for a previous study but it would be pretty interesting to find a mab that had any oral bioavailability.

by csours 11y ago

deleted 11y ago

[deleted]

awalton 11y ago

I found a French website claiming the drug is BIA 10-2474, with reference to a patient who received an offer to join this trial but decided not to: http://www.breizh-info.com/2016/01/15/rennes-biotrial-bialessai-therapeutique/ http://www.breizh-info.com/2016/01/15/rennes-biotrial-biales... And of course, the information around this particular drug is completely missing or intentionally vague. edit: there seems to be a lot of people who believe the drug is a FAAH2 inhibitor, based on previous work from the same company, Bial Pharmaceuticals out of Portugal. The drug works on/around endocannabinoids, which might be why the media was confused about this being cannibis related.

gerbilly 11y ago
In the video they say that the drug in question is intended to control pain via the endocannabinoid system. She was also very careful to insist that the drug neither contains cannabis or any substance derived from cannabis.

gregmac 11y ago

TGN1412 was a different trial that happened in 2006: it's mentioned in the article as a similar incident because it hospitalized six men.

csours 11y ago
Sorry about that, article was confusing.

jonlucc 11y ago

I believe the drug you reference is discussed as a previous case in which people were injured during clinical trials. The current casualties are part of a test of a different investigational cannabinoid pain-killer.

csours 11y ago

Replying as I can no longer update: I misread the article. I would follow this post [1] by Derek Lowe for more accurate info. If preliminary reports are correct the drug in question may be a FAAH inhibitor [2] which could lead to increased Andandamide [3] 1. http://blogs.sciencemag.org/pipeline/archives/2016/01/15/a-clinical-disaster-in-france http://blogs.sciencemag.org/pipeline/archives/2016/01/15/a-c... 2. https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase 3. https://en.wikipedia.org/wiki/Anandamide https://en.wikipedia.org/wiki/Anandamide

drmilsurp 11y ago

I see in later replies that this was for a previous study but it would be pretty interesting to find a mab that had any oral bioavailability.